|
|
|
Volumn 23, Issue 2, 2009, Pages 194-196
|
|
The growing importance of skin toxicity in EGFR inhibitor therapy
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CETUXIMAB;
CLINDAMYCIN;
DOXYCYCLINE;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;
ERITEX;
ERLOTINIB;
ERYTHROMYCIN;
FUSIDIC ACID;
GEFITINIB;
HYDROCORTISONE;
MENADIONE;
METRONIDAZOLE;
MINOCYCLINE;
PANITUMUMAB;
PIMECROLIMUS;
PLACEBO;
SUNSCREEN;
TAZAROTENE;
TETRACYCLINE;
UNCLASSIFIED DRUG;
VERUTEX;
CLINICAL TRIAL;
COLORECTAL CANCER;
DRUG ERUPTION;
EVIDENCE BASED MEDICINE;
HEAD AND NECK CARCINOMA;
HUMAN;
LUNG CANCER;
MALIGNANT NEOPLASTIC DISEASE;
MEDICAL DECISION MAKING;
MEDICAL RESEARCH;
PANCREAS CANCER;
PAPULAR RASH;
PRACTICE GUIDELINE;
QUALITY OF LIFE;
REVIEW;
SKIN DISEASE;
TREATMENT INDICATION;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DERMATOLOGIC AGENTS;
DRUG ERUPTIONS;
EMOLLIENTS;
EVIDENCE-BASED MEDICINE;
HUMANS;
PRACTICE GUIDELINES AS TOPIC;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
|
|
EID: 63249108255
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (21)
|
|
References (0)
|
